The BioNTech SE ADR BNTX inched 0.49% higher to $118.22 Friday, on what proved to be an all-around mixed trading session for ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

BioNTech's shares have experienced a remarkable upswing, with the stock price soaring to $130.90 on NASDAQ, marking a 6.0% increase in the latest session. This surge represents a significant ...

The BioNTech SE ADR BNTX rallied 1.59% to $117.64 Thursday, on what proved to be an all-around favorable trading session for ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...